Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310672 · ClinicalTrials.gov registry record · Phase 4
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
A Phase 4 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT02310672 is a Phase 4 study that has completed, run by Actelion. The registered enrollment target is 89 participants.
The verdict
NCT02310672, a Phase 4 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year. Patients undergo right heart catheterization (RHC) at baseline and Week 26. They also undergo cardiac magnetic resonance imaging (MRI) at baseline, Week 26 and Week 52. Safety is monitored throughout the study. The study has three stub-studies. Each patient can participate in no sub-study or in one sub-study. The sub-studies are: (1) metabolism sub-study (with PET-MR scans); (2) biopsy sub-study (biopsies taken during the RHC); (3) Echo sub-study.
Interventions
- DRUG Macitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2015-06-01 |
| Est. Completion | 2019-09-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02310672
The ClinicalTrials.gov registry entry for NCT02310672 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Macitentan is the first listed.
NCT02310672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02310672 about?
NCT02310672 is a clinical study titled "REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension". The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year. Patients undergo right heart catheterization (RHC) at baseline and Week 26. They also undergo ca...
What is the current status of trial NCT02310672?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2015-06-01. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT02310672?
The interventions under investigation include: Macitentan (DRUG).
Who is sponsoring clinical trial NCT02310672?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.